Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2393910 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 20 mg LY2393910 | EXPERIMENTAL | - |
| 60 mg LY2393910 | EXPERIMENTAL | - |
| 150 mg LY2393910 | EXPERIMENTAL | - |
| 450 mg LY2393910 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LY2393910 | DRUG | as capsules, administered orally once daily for two weeks |
| Placebo | DRUG | as capsules, administered orally once daily for two weeks |
Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus * Must be on a stable treatment regimen (maintained on diet/exercise therapy with or without metformin) for at least 4 weeks prior to study entry * Have a glycated haemoglobin (HbA1c) value greater than or equal to 6.5% and less than or eq...
LY2393910 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with Type 2 diabetes to evaluate its safety, tolerability, and pharmacokinetics.
The molecular target of LY2393910 has not been disclosed. The drug is a small molecule being investigated for its potential role in managing Type 2 Diabetes Mellitus, but its specific mechanism of action is not publicly available at this time.
LY2393910 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational drug for the treatment of Type 2 Diabetes Mellitus.
LY2393910 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is still in the early stages of clinical testing, with one Phase 1 trial completed to date.
LY2393910 has one completed clinical trial, identified as NCT01253278, titled "A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients." This Phase 1 study enrolled 38 participants in Germany and was a randomized, double-blind, placebo-controlled trial. The trial has been completed, and no active trials are currently listed.